Life Sciences Deals, Growth, and the New M&A Market: EY's Subin Baral on What Comes Next
BioTalk with Rich BendisShow Notes
In this episode of BioTalk with Rich Bendis, Subin Baral, Partner at Ernst & Young LLP and EY-Parthenon Global Life Sciences Deals Leader, joins the conversation to discuss the changing life sciences dealmaking environment and what it means for companies, investors, and regional innovation ecosystems.
Subin shares how life sciences companies are shifting from defensive portfolio management toward acquiring earlier-stage assets, technologies, and capabilities that can support long-term growth. He discusses why buyers are looking earlier in the development cycle, what makes an asset attractive in the current market, and why differentiated science, strong data, and flexible deal structures matter more than ever.
The conversation also explores the current M&A environment, including EY's view that life sciences M&A activity has accelerated significantly, with stronger activity across both biopharma and MedTech. Subin touches on the broader mix of buyers entering the market, the role of mid-sized companies, and how areas such as oncology, immunology, neuroscience, cell and gene therapy, ADCs, bispecifics, AI, data, and quantum may shape future deal activity.
Rich and Subin also discuss the growing role of China in global life sciences innovation, the challenges facing early-stage companies as funding remains difficult, and how startups can think about partnerships, capital access, and strategic flexibility in a more disciplined market.
The episode also looks at what these trends mean for regions like the BioHealth Capital Region, including how emerging ecosystems can build visibility, strengthen networks, support differentiated technologies, and position companies for future capital, partnerships, and deal activity.
Editing and post-production work for this episode was provided by The Podcast Consultant.
Subin is a partner at Ernst & Young LLP and the EY-Parthenon Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies with transformational transactions. Subin has extensive global experience serving as a buy- and sell-side transaction advisor for Fortune 500 companies, including in corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors. Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from startups to public companies. He frequently speaks at life sciences events about sector trends and acquisitions and divestitures topics. He received his Master of Commerce from Macquarie University in Sydney, Australia. He is a chartered accountant from the Institute of Chartered Accountants of Australia and New Zealand.
More from BioTalk with Rich Bendis
In this episode of BioTalk with Rich Bendis, Maureen L. Mulvihill, Ph.D., Founder, President, and CEO of Actuated Medical, discusses the company's 2026 BioHealth Capital Region Crab Trap Competition win and its work advancing medical device innovation from central Pennsylvania. Maureen shares how Actuated Medical grew from a focus on improving patient outcomes through innovative motion into a company with more than $50 million in non-dilutive funding, 43 patents, 9 FDA 510(k) clearances, and FDA-registered, ISO 13485-certified manufacturing infrastructure. Rich and Maureen also discuss the TubeClear system, Actuated Medical's first FDA-cleared device, including the story of the first patient it helped at Walter Reed, and how that experience shaped the company's mission. The episode also explores NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform, including how earlier work in tissue penetration led to brain implant technology, DARPA-supported commercialization, global research use, and the company's next steps toward clinical applications. Maureen also shares what comes next for Actuated Medical, including its focus on NeuroGlider, upcoming visibility at the MedTech Conference in Boston, and her advice to entrepreneurs building medical device companies: persistence matters. Editing and post-production work for this episode was provided by The Podcast Consultant. Maureen L. Mulvihill, Ph.D., is Founder, President, and CEO of Actuated Medical, a medical device company advancing the NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform for neurotechnology, brain therapeutics, and longevity-related medicine. Under her leadership, Actuated Medical has secured more than $50 million in non-dilutive funding, developed a portfolio of 43 patents, achieved 9 FDA 510(k) clearances, and earned two SBA Tibbetts Awards recognizing excellence in commercialization. Dr. Mulvihill serves on the Board of Directors of AdvaMed, the AdvaMed Accel Board, the Life Sciences Pennsylvania Board of Directors, chairs the Industrial Advisory Board for the Penn State Center for Biodevices, and serves on the Kish Bank Regional Advisory Board. She has received more than 35 entrepreneurship and leadership awards, including being named 2020 Life Sciences Pennsylvania CEO of the Year and leading Actuated Medical to First Place in the 2026 BioHealth Capital Region Crab Trap Competition. She earned her Ph.D. from The Pennsylvania State University.
In this episode of BioTalk with Rich Bendis, Ralf Huss, MD, PhD, Managing Director and CEO of BioM Biotech Cluster Development GmbH and spokesperson for the Bavarian Biotechnology Cluster, joins the conversation to discuss Bavaria's biotechnology ecosystem and BioM's role in moving science toward commercialization. Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation. Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM's work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role. The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region. Editing and post-production work for this episode was provided by The Podcast Consultant. Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe's leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.
In this episode of BioTalk with Rich Bendis, Tammi Thomas, President of TEDCO, joins the conversation to discuss how Maryland is helping entrepreneurs move ideas from research and concept to market.
In this episode of BioTalk with Rich Bendis, Matt Adams, Chief Executive Officer of BrainScope, joins the conversation to discuss how the Rockville-based company is working to bring objective brain function measurement into real-world clinical care.
In this episode of BioTalk with Rich Bendis, Travis McCready, Head of Industries, Leasing Advisory at JLL, joins the conversation to discuss quantum computing, why real estate professionals are paying attention, and what this emerging technology could mean for regions like the BioHealth Capital Region.